The modular nature of bradykinin-potentiating peptides isolated from snake venoms

Juliana Mozer Sciani and Daniel Carvalho Pimenta*

Abstract

Bradykinin-potentiating peptides (BPPs) are molecules discovered by Sergio Ferreira – who found them in the venom of Bothrops jararaca in the 1960s – that literally potentiate the action of bradykinin in vivo by, allegedly, inhibiting the angiotensin-converting enzymes. After administration, the global physiological effect of BPP is the decrease of the blood pressure. Due to this interesting effect, one of these peptides was used by David Cushman and Miguel Ondetti to develop a hypotensive drug, the widely known captopril, vastly employed on hypertension treatment. From that time on, many studies on BPPs have been conducted, basically describing new peptides and assaying their pharmacological effects, mostly in comparison to captopril. After compiling most of these data, we are proposing that snake BPPs are ‘modular’ peptidic molecules, in which the combination of given amino acid ‘blocks’ results in the different existing peptides (BPPs), commonly found in snake venom. We have observed that there would be mandatory modules (present in all snake BPPs), such as the N-terminal pyroglutamic acid and C-terminal QIPP, and optional modules (amino acid blocks present in some of them), such as AP or WAQ. Scattered between these modules, there might be other amino acids that would ‘complete’ the peptide, without disrupting the signature of the classical BPP. This modular arrangement would represent an important evolutionary advantage in terms of biological diversity that might have its origins either at the genomic or at the post-translational modification levels. Regardless of the modules’ origin, the increase in the diversity of peptides has definitely been essential for snakes’ success on nature.

Keywords: Bothrops jararaca, Venom, Snake venom, Bradykinin-potentiating peptides, BPP, Modules

Background

Snakes are elongated, legless, carnivorous reptiles of the order Squamata and suborder Serpentes (Ophidia) found on every continent except Antarctica [1]. They are thought to have evolved from either burrowing or aquatic lizards, perhaps during the Jurassic period, with the earliest known fossils dating to between 143 and 167 million years ago. The diversity of modern snakes appeared during the Paleocene period (66 to 56 million years ago). The oldest preserved descriptions of snakes can be found in the Brooklyn Papyrus (450 BC), a manuscript from the ancient Egypt that systematically describes snakes and different treatments for snakebites [2].

Currently, there are circa 3400 snakes species, divided into 18 families. Although most species are non-venomous, those that have venom use it primarily to kill and subdue prey rather than for self-defense [3]. Elapidae and Viperidae are two examples of such families that might be dangerous to humans, once the specimens contain highly toxic venom [1].

Snake venom, which is a highly modified saliva produced by modified salivary glands, is injected by specialized hollow teeth. It is thought to have evolved from simple sets of proteins through gene duplication and natural selection, followed by functional diversification [4]. Elapidae venoms are, in general, more neurotoxic whereas Viperidae venoms act more on coagulation factors [5, 6].

Bothrops (Serpentes: Viperidae: Crotalinae) is an endemic genus to Central and South America, and contains 32 species. Among its members, Bothrops jararaca – native to Brazil, Paraguay and Northern Argentina – deserves credit for being the species from which Sergio Ferreira isolated the bradykinin-potentiating factors (BPF) in the 1960s [7]. Later,
these factors were identified to be peptides, named bradykinin-potentiating peptides (BPPs), and were the molecular basis for the design of captopril, the world famous antihypertensive drug, developed by Cushman and Ondetti [8].

BPPs are proline-rich peptides, known to inhibit the angiotensin-converting enzyme (ACE). This enzyme is responsible for the conversion of angiotensin I into angiotensin II, which is a potent vasoconstrictor and hypertensive agent. By inhibiting ACE, BPPs inhibit angiotensin II formation, reducing the blood pressure [9]. Moreover, since this enzyme is able to cleave bradykinin as well (a hypotensive peptide), its inhibition is comprised of two different mechanistic targets (angiotensin and bradykinin) causing global hypotensive effects [10].

The first BPP was discovered by Ferreira and Rocha e Silva [11] and termed as such due to its pharmacological effect, i.e., literally potentiate/enhance the effect of bradykinin (BK), in comparison to the same BK dose administered prior to the BPP treatment, without presenting any hypotensive effect per se. Since that time, biological driven assays have led to the discovery of several BPPs from many sources, such as scorpion venoms, tree-frog skin secretions and in the venom of snakes from other species [12–16]. Nevertheless, since the term BPP actually describes an effect and not a structural motif, there are many related and unrelated peptide sequences that can elicit such BK potentiation (Table 1 presents some of these peptides). Therefore, this paper will focus solely on snake BPPs.

**Structure of BPPs**

Snake BPPs are (mostly) < 14-mer proline-rich peptides (PRPs), presenting three distinct features: i) an almost invariable pyroglutamic acid at the N-terminus; ii) the presence of a Pro residue at the C-terminus for peptides containing up to five residues; iii) the presence of the tripeptide Ile-Pro-Pro at the C-terminus of >5-mer peptides containing up to 14 residues [17]. Therefore, the general structure pattern of BPPs would be:

\[<E−Xn−P−Xn−P−Xn−I−P−P\]

\(<E: \text{pyroglutamic acid}; X: \text{any amino acid, but Cys}\)

With a rather limited amino acid substitution capacity, in order to fit in this criterion, it is not surprising that many BPPs are very similar, and also that the exact same peptide sequences can be found in different species of snakes. For instance, larger BPPs (> 10 amino acids) tend to have the tripeptide IPP at the C-terminus, whereas the shorter sequences (5, 6 and 7 mers) preserve only the N-terminal part of the scaffold presented above. Moreover, some larger BPPs possess the same N-terminal amino acid sequence as others shorter BPPs. One example comprises BPPs 5b (<EWPRP) and 9a (<EWPRPQIPP), in which BPP 5b is, in fact, the N-terminus of BPP 9a [17]. BPP 5b is also very similar to BPP 5a (<EKWAP), the one that served as template for the development of captopril [11]. Naturally, these similarities and differences also occur at the pharmacological and enzymatic levels, yielding different k values according to the substituted amino acid and the performed biological assay [18].

**Modular sequences**

In 2004, Ianzer et al. [17] identified several BPPs, either ‘new’ or ‘old’ peptides (previously described) in B. jararaca venom, using both biological monitored screening and the incipient (at the time) de novo peptide sequencing by tandem mass spectrometry (MS/MS), after a straight forward two-step liquid chromatography sample preparation procedure. Currently, when revisiting that paper [17], these authors could notice that two out of the five new sequences described were mere variations of already known peptides, with an extra -WAQ- sequence buried within.

This observation triggered the authors’ curiosity to revisit other studies as well, particularly the ones containing description of new/novel BPPs. The work by Pimenta et al. [19] analyzed several B. jararaca venom samples, from both siblings born and raised in captivity and wildlife captured individuals. It describes that the peptide contents of the venom is different in male and female individuals. Authors sequenced the female-exclusive peptides and observed that those were the known BPPs 9a, 10b, 10c and 11a, but lacking the C-terminal peptide sequence -QIPP. They concluded – at the time – that those were ‘cleaved/processed’ peptides present only in female individuals. However, in light of this new proposed point of view, it would be more likely that the -QIPP `module’ would be added in males, rather than removed in females. A few points corroborate this idea: i) the ‘processed’ QIPP peptide was not observed in any venom of any individual, by any technique (ESI and/or MALDI) in that study; and ii) the processing site would involve an enzyme capable of cleaving the Pro-Gln peptide bond, which is quite specific. A query for this specificity at the MEROPS data base [20] yields few enzymes, including

| Name (Source) | Sequence |
|---------------|----------|
| BPP 11a (Bothrops jararaca)\(^a\) | <EWPRPTEPQIPP |
| 108-111\(^a\)casein\(^b\) (Bos taurus) | EMPFFK |
| Phypo Xa (Phyllomedusa hippocordialis)\(^c\) | <EFRPSVQIPP |
| BPP-Si (Scaptocosa raptoria)\(^d\) | <EAPWPDTISP |
| K12j (Buthus occitanus)\(^e\) | LRDYANVINGPVEAGPPA |
| Tsh-Ip-Hk (Tityus serrulatus)\(^f\) | AEIDFSGIPEDIIKQIKETNAKPAPA |
| LVV-Hemorphin-7\(^g\) (Canis lupus familiaris) | LVYYPWTQRF |

\(<E: \text{pyroglutamic acid}\)

\(^a\) [17] \(^b\) [31] \(^c\) [32] \(^d\) [29] \(^e\) [12] \(^f\) [33]

papain and other cysteine peptidases, as well as prolyl oligopeptidase (POP) and some matrix metallopeptidases (MMPs), including a disintegrin and metallopeptidase (ADAMs). Taking into account that no POP or cysteine peptidase were ever found in snake venom and that there are published reports demonstrating that the MMPs/SVMPs (snake venom metallopeptidase) present in the venom are catalytically inactive due to a three-component inhibition system (low pH, Ca²⁺ chelation and peptide inhibition; [21]), the -QIPP module addition in males turns to be much more feasible than the -QIPP removal in females, according to our current proposal.

Further exploration of published data on snake BPPs led us to identify another ‘module’: -AP-. This dipeptide module, however, possess an interesting characteristic: it is mainly located at the C-terminal of the BPPs, as one can observe for BPP-AP from B. jararacussu (<EARPHPHIPPPAP) and BPP 12d from B. cotiara and B. fonsecai (<ENWPHPMMPPAP). Zelanis et al. [22], when analyzing the peptidome of B. jararaca, were able to identify the presence of BPP 11e with AP at the C-terminal in both adults and newborn specimens. This same study presents BPPs with extra amino acids, but we could not classify them as ‘modules’ (yet) and neither did the authors, which considered those peptides to be mere ‘variations’ and/or ‘redundancies’ of the snakes’ peptide repertoire. Based on this rationale, the very first/primordial modular BPP would be BPP 5a (<EKWAP), which is nothing more than the intrinsic metallopeptidase inhibitor <EKW [21] with the -AP- module addition.

Nevertheless, some Crotalus sp. BPPs present the -AP-module within the sequence, such as BPPs 11b and 11c (<EGGAPWNIPP and <ESAPGNEAIPPA, respectively). BPP 13d seems to have duplicated this modular insertion: <EGRAPHPPIPPAP. Moreover, a very interesting new BPP isolated from Bitis gabonica rhinoceros (APQERGP-PEIPP) is, so far, the sole BPP with the -AP- module at the N-terminal [22–25].

Other internal sequences that appear to be modules are: -PRP- and -PHP-. BPP 10b–F and 10c–F would fit in the same ‘primordial’ BPP category as BPP 5a. For 10b–F and 10c–F would be the MMP inhibitor <ENW, plus the -PRP- and -PHP- motifs. Nevertheless, these are the only examples of the existence of these modules (-PRP- and -PHP-), e.g., these peptides have been actually and independently identified. No other desPRP or desPHP BPPs have been described so far.

The roadmap to the BPPs

Through analyses of the BPP sequences, based on sequence alignments and other structural features, we propose that there are two possible structural motifs for the BPPs: the ‘mandatory’ and the ‘optional’. The mandatory motifs would be:

\[(N\text{-terminal})(\text{Internal})(C\text{-terminal})\]
\[<\text{E}/<\text{EXW}-\text{PZP}-\text{PPIPP}\]
\[(X = N \text{ or } K; Z = R, H \text{ or } G)\]

whereas the optional motifs would be:

\[\text{AP-}W\text{A}Q\text{-}QIPP\]

Therefore, by arranging and combining the modules above, one ought to be able to ‘recreate’ all described BPPs and, eventually, predict the existence of undiscovered molecules. Examples of actual peptides bearing this modular assembly are: (Fig. 1).

Therefore, other peptides, not limited to these, must exist, based on different/random combinations of mandatory and optional modules. Below, we propose a made up sequence comprised of one mandatory and two optional motifs:

\[<\text{EKW} + \text{AP} + \text{QIPP}\]

When querying UniProt, there is close call for the Echis ocellatus SVMP inhibitor 02D01 (UniProt A8YPR6), which is a precursor of many peptides, including this sequence:

\[\ldots 159\text{QKWQPQIP}^{166}\ldots \]

One must take into account that the pyroglutamic acid is a post-translational modification that is normally annotated as glutamine (Gln; Q) in the precursor protein in the deposited sequences.

![Fig. 1 Actual modular BPPs. In black: mandatory/optional pieces. In grey: additional residues](image)
In fact, A8YPR6 precursor seems to be very much like the B. jararaca BPP/C-type natriuretic peptide precursor (UniProt Q6LEM5), i.e., a multiple peptide precursor, containing several BPPs. The ‘test’ performed with the sequence above aligns with ten more internal peptides from this E. ocellatus precursor (39–48; 51–60; 75–84; 87–96; 99–108; 111–120; 135–144; 147–156; 63–72; 244–246; Uniprot numbering; listed in decreasing score order).

Another test subject for our hypothesis could be:

< EKW + PRP + AP + QIPP

This yields good matching to BPP 11, from B. neuwiedi (UniProt P0C7S5).

...2 WPRPTPQIPP

As well as other lower scores matches among several other BPPs and BPP/C-natriuretic peptide precursors, as commented above, there is little room for sequence variation under the rigid constraints of the canonical BPP. This exercise would go on and on and as our hypothesis seems to be valid.

**Module distribution**

Based on the 87 currently available deposited snake BPPs (Table 2), we have performed some sequence feature analyses in order to evaluate whether our modular proposal is subsided by the actual amino acid composition/distribution. First, we have compared the percent amino acid distribution in the whole proteome (UniProt Release 2016_10 of 2 Nov. 2016 of UniProtKB/TrEMBL containing 70,656,157 sequence entries, comprising 23,670,752,099 amino acids; https://web.expasy.org/docs/relnotes/relstat.html) with the amino acid composition of the peptides listed in Table 2. Figure 2 presents the distribution of the percent composition of the samples.

One can clearly observe that the UniProt amino acid composition follows an almost identical distribution, being Leu the most abundant amino acid (~10%) and Cys and Trp the rarest ones (~1%), e.g., a ten-fold maximum variation. On the other hand, the snake BPPs amino acid composition is rather heterogeneous. Proline is the most copious amino acid, corresponding to nearly 40% of the total. Not taking into account that — so far — no BPP has ever been described containing a Cys residue, Phe and Tyr are the least common amino acids, in a 40:1 relationship. Although Gln appears at the second position, this figure comprehends both glutamine and pyroglutamic acid, a consequence of the UniProt notation for the N-terminal substitution. The significantly abundant amino acids ranking second are Gly, Ile, Trp and Arg that together (255 AA) add up to more than the remaining 13 amino acids (193 AA). According to this analysis, the BPPs can — undoubtfully — be classified as proline-rich peptides.

Next, we have tested whether these amino acids are randomly distributed or would they be arranged in preferred groups. Table 3 presents the average dipeptide composition of all possible amino acids but Cys. The frequency is presented in percent values together with a gray bar corresponding to the figure for better visualization. One can observe that Pro not only is the most common amino acid but also that the dipeptide Pro-Pro is the most frequent amino acid combination, followed by Ile-Pro, Trp-Pro and Arg-Pro; not surprisingly the same second-most abundant amino acids. This table provides a clear depiction of the preferred amino acid pattern arrangement instead of a random distribution.

After performing such ‘quality control’ steps, it is our understanding that the amino acids present in snake BPPs do follow a pattern and that this pattern can be categorized into ‘modules’ that can also be analyzed according to their distribution, based on the current availability of peptide sequences. Figure 3 shows the percent distribution of the modules we were able to identify in the snake BPPs. Furthermore, this figure group the PRP, PHP and PGP modules in a ‘generic’ PXP module that corresponds to more than half of the modular instances detected. If one groups the IPP present in the QIPP and PPIPP modules, one reaches 25% (less than half of the PXP modules distribution). This observation becomes quite important when the majority of the papers dealing with snake BPPs state that ‘canonical BPPs are proline rich peptides presenting a pyroglutamic acid at the N-terminal and the IPP tripeptide at the C-terminal’.

**Conclusion**

With no available knowledge on the molecular genetics of any Bothrops sp. snake (the main BPP producing snakes), nothing can be inferred about the chromosomal origins of these modules; nevertheless, their existence and participation in the ‘creation’ of the different sequenced BPPs is unequivocal.

On the other hand, by synthesizing peptides as modules, the variability increases several times, what would also increase the number of molecules in venom. The variability of molecules leads into improved biological activities, important for more efficient prey envenomation. This would represent a great evolutionary advantage, once the animal genome would not be as complex as the number of secreted peptides, similar to the de novo antibody production [26]. Nevertheless, complimentary genetic studies are needed to evaluate this hypothesis. What has been previously postulated is that the snake venom gland has...
| BPP10a       | QSWPQGPNIPP          | BPP-11b-CROA   | QGGWPRNIPPP |
| BPP6a       | QSWPQP               | BPP-11c-CROV   | QSAPGNEAIPP |
| BPP13a + QQA | QWQAQGWPRPGEIIPP    | BPP-11-BOTAL   | QWPDPDSOIPP |
| BPP13a       | QGGWPRPGEIIPP       | BPP-11-NEW     | QGGAGWPPIPP |
| BPP10c + QQA | QQAQWNWPPIQPP       | BPP-13a        | QGGWPRPGEIIPP |
| BPP10c       | QNWPHP               | BPP-2-Glo      | QGRRPPHIPPP |
| BPP11b       | QGRAPGPIPP           | BPP-POL-236    | QLWPRPQIPP |
| BPP11b       | QWAP                 | BPP-7b         | QNWPSK |
| BPP12b       | QWGRPPGPPIPP        | BPP-7c         | QRWPSK |
| BPP-AP       | QARPPHIPPIPA        | BPP-8a         | QNAPSPK |
| BPP-C-AP     | QGRRAPPPIPP         | BPP-9a         | QWPRPQIPP |
| BPP-AP       | QARPPHIPPIPA        | BPP-10d        | QNWPHPPMIPP |
| BPP-AP       | QRAPHIPPIPA         | BPP-10e        | QNWPSKQVPP |
| BPP-Ahbb1    | QKWDP                | BPP-11 f       | QNAHPKVV |
| BPP-Ahbb2    | QPHESP               | BPP-11 h       | QGRHIPPIPP |
| BPP-AP       | QRWPHLEIPP          | BPP-11j        | QNRHIPPIPP |
| BPP-AP       | QKWPPGHHIP          | BPP-Pb         | QTLQELPIPP |
| BPP-AP       | QGWPPGHHIP          | BPP-12a        | QGWAWPRPQIPP |
| BPP-AP       | QKWPPGHHIP          | BPP-12b        | QLGDPQPPQIPP |
| BPP-AP       | QKWDPPHIIPP         | BPP-12d        | QNWPHPPMIPP |
| BPP-AP       | QKWDPPHIIPP         | BPP-12e        | QARPRGPPIPP |
| BPP-AP       | QKWPRPPTQIPP        | BPP-13a        | QGGWPRPGEIIPP |
| BPP-AP       | QSKPGRSPPISP       | BPP-13b        | QGLDPQPPGEIIPP |
| BPP-AP       | QWMPEGRRPHHIPPP     | BPP-13c        | QGRHIPPIPP |
| BPP-AP       | QGRRPSEVPP          | BPP-13d        | QGRAPHIPPIPP |
| BPP-AP       | QNWXSP               | BPP-TmF        | QGRPLGPIPP |
| BPP-AP       | QWXQWRPHLEIPP       | BPP-Phypo-Xa   | QFRPSQYPIPP |
| BPP-AP       | QWRPHLEIPP          | BPP-VIPAS      | QGWPQKPVPP |
| BPP-C-AP     | QNWKSP               | BPP-S5b-9a-F   | QWPRP |
| BPP-C-AP     | QARESP               | BPP-10b-F      | QNWPRP |
| BPP-AP       | QRWPHLEIPP          | BPP-11a-F      | QWPRPQTP |
| BPP-AP       | QNWPRPQIPP          | BPP-F-AK       | QLWPRPQIPP |
| BPP-AP       | QNWKSP               | BPP-3-new      | QGGWPRPGEIIPP |
| BPP-AP       | QREWPRPQIPP         | BPP-S412       | QGRRPPQIPP |
| BPP-AP       | QKEXPGSPPISP       | BPP-S51        | QWGQHPNIPP |
| BPP-AP       | QOWPRDAPAPIPP      | BPP-11a        | QWPPGSHIPP |
| BPP-AP       | QAPWPDTSIPP         | BPP-11b-CRO    | QGAPWNPPIPP |
| BPP-AP       | QGRRPPGPIPP        | BPP-11b-CRO    | QGAPWNPPIPP |

N-terminal Q denotes pyroglutamic acid
Most BPP’s nomenclature depends on: i) the number of amino acids of the peptide (BPP-5 has five amino acids, BPP-10, ten amino acids and so on); ii) the order of discovery of the peptide. BPP-10a was the first to be described, then BPP-10b, 10c, and so on; and iii) a possible extra feature. For instance, −F indicates peptides present only in females. -AP denotes an extra dipeptide AP added to an existing sequence.

In bold, the peptide names as deposited in the UniProt database.
undergone a process of gene recruitment and duplication, resulting in toxic/enzymatic variability [27].

Kininogens have already been reported in the snake plasma and different kinins isolated from fish, amphibians and birds [28]. Altogether, there might be possible that there were original kinins in the snake plasma (although none has been described yet), derived from the kininogen, which have undergone a recruitment process on the venom gland. In the gland, the kinins would have turned into the BPPs and kininogen, into the BPP/C-type natriuretic peptide precursor. This would explain why the long sought 'endogenous BPP' has never been found in mammals, no matter how hard some groups have tried [29].

In fact, according to our understanding and the currently proposed module approach, kinins would be the ‘original BPPs’. It seems that the Amphibia have already experimented this theme by long secreting bradykinin-related peptides (BRP) through the skin. We have previously explored some structural features of these BRPs when describing three new BRPs in Phyllomedusa [30] and concluded – once more – that there is very little room for sequence variation when there are so many structural constrains involved. The same happened when we described the first canonical BPP not from snake venom, but from the tree frog P. hypochondrialis (BPP Phypo-Xa) [13]. The structural features analyses of this 10-mer canonical BPP, known at that time, points out to a very high degree of conservation, compared to others BPPs. Unfortunately, few kininogens and BPP/C-natriuretic precursor sequences are currently available to prove this hypothesis by constructing phylogeny trees.

Table 3 Dipeptide frequency distribution

| Amino acid | Ala | Asp | Glu | Phe | Gly | His | Ile | Lys | Leu | Met | Asn | Pro | Gln | Arg | Ser | Thr | Val | Trp | Tyr |
|------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala        | 0.104 | 0.248 | 0.104 | 0 | 0 | 0 | 0 | 0 | 1.677 | 0.399 | 0.755 | 0 | 0 | 0.104 | 0 | 0 | 0.096 | 0 |
| Asp        | 0.104 | 0.104 | 0.164 | 0 | 0.104 | 0 | 0 | 0 | 0.104 | 0.104 | 0 | 0 | 0 | 0.104 | 0 | 0 | 0.104 | 0 | 0 |
| Glu        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0.096 | 0 | 0.104 | 0 | 0 | 0 | 0 | 0.383 | 0 | 0 | 0.115 | 0.104 | 0 | 0 |
| Phe        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.312 | 0 | 0 | 0 | 0.104 | 0 | 0 |
| Gly        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.312 | 0.115 | 0 | 0 |
| His        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.115 | 0 |
| Ile        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lys        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0.104 | 0 | 0 | 0.312 | 0 | 0 | 0 | 0.115 |
| Leu        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Met        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asn        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0.104 | 0.104 | 0 | 0.209 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.76 |
| Pro        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0.104 | 0.104 | 0 | 0.209 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.76 |
| Gln        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0.104 | 0.104 | 0 | 0.209 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.76 |
| Arg        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0.104 | 0.104 | 0 | 0.209 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.76 |
| Ser        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0.104 | 0.104 | 0 | 0.209 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.76 |
| Thr        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0.104 | 0.104 | 0 | 0.209 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.76 |
| Val        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0.104 | 0.104 | 0 | 0.209 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.76 |
| Trp        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0.104 | 0.104 | 0 | 0.209 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.76 |
| Tyr        | 0.104 | 0.104 | 0.104 | 0 | 0.104 | 0.104 | 0.104 | 0 | 0.209 | 0.104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.76 |
In sum, it is our understanding the snake BPPs follow the modular construction pattern and, as far as new sequences are discovered, more patterns may be perceived. This modular design would explain the variability of peptides present in the venom and the consequent evolutionary success of these animals.

Abbreviations
ACE: Angiotensin-converting enzyme; ADAMs: A disintegrin and metallopeptidase; BK: Bradykinin; BPP: Bradykinin-potentiating factor; BPPs: Bradykinin-potentiating peptides; BRP: Bradykinin-related peptides; MWPs: Matrix metallopeptidases; MG/MS: Tandem mass spectrometry; POP: Prolyl oligopeptidase; PRPs: Proline-rich peptides; SVMps: Snake venom metallopeptidase

Acknowledgments
We are grateful to Dr. Ivo Lebrun for critical review of this manuscript.

Funding
The authors acknowledge the financial support of FAPES, CNPq, CAPES and FINEP. DCP is a CNPq fellow researcher (303792/2016–2017).

Authors’ contributions
All authors contributed to drafting and revising the manuscript. In addition, they all read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 18 May 2017 Accepted: 21 September 2017
Published online: 26 October 2017

References
1. Kasturiatne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, et al. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 2008;5(11):e218.
2. Caldwell MW, Nydam RL, Palci A, Aposteguia S. The oldest known snakes from the middle Jurassic-lower cretaceous provide insights on snake evolution. Nat Commun. 2015;6:5996. https://doi.org/10.1038/ncomms6996.
3. Weinstein SA. Snake venoms: a brief treatise on etymology, origins of terminology, and definitions. Toxicon. 2015;103:188–95.
4. Fry BG, Casewell NR, Wüster W, Vidal N, Jackson TNW, Young B. The structural and functional diversification of the Viperidae snake venom system. Toxicon. 2012;60(4):434–48.
5. Bauchot R. Snakes: a natural history. New York City, NY, USA: Sterling Publishing Co; 1994.
6. Caldwell MW, Nydam RL, Palci A, Aposteguia S. The oldest known snakes from the middle Jurassic-lower cretaceous provide insights on snake evolution. Nat Commun. 2015;6:5996. https://doi.org/10.1038/ncomms6996.
7. Weinman SA. Snake venoms: a brief treatise on etymology, origins of terminology, and definitions. Toxicon. 2015;103:188–95.
8. Verano-Braga T, Rocha-Resende C, Silva DM, Ianzer D, Martin-Eauclaire MF, Bougis PE, et al. Hypertension. 1991;79(4):589–92.
9. Fernandez JH, Neshich G, Camargo AC. Using bradykinin-potentiating peptide structures to develop new antihypertensive drugs. Genet Mol Res. 2004;3(4):554–63.
10. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension. 1991;79(4):589–92.
11. Fernandez JH, Neshich G, Camargo AC. Using bradykinin-potentiating peptide structures to develop new antihypertensive drugs. Genet Mol Res. 2004;3(4):554–63.
12. Dendorfer A, Wolfrum S, Dominiak P. Pharmacology and cardiovascular implications of the kinin-kallikrein system. Jpn J Pharmacol. 1999;79(4):403–26.
13. Dendorfer A, Wolfrum S, Dominiak P. Pharmacology and cardiovascular implications of the kinin-kallikrein system. Jpn J Pharmacol. 1999;79(4):403–26.
14. Fernandez JH, Neshich G, Camargo AC. Using bradykinin-potentiating peptide structures to develop new antihypertensive drugs. Genet Mol Res. 2004;3(4):554–63.
15. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension. 1991;79(4):589–92.
16. Fernandes JH, Neshich G, Camargo AC. Using bradykinin-potentiating peptide structures to develop new antihypertensive drugs. Genet Mol Res. 2004;3(4):554–63.
17. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension. 1991;79(4):589–92.
18. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension. 1991;79(4):589–92.
19. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension. 1991;79(4):589–92.
20. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension. 1991;79(4):589–92.
ionization tandem mass spectrometry after a two-step liquid chromatography. Peptides. 2004;25(7):1085–92.

18. Camargo AC, Ianzer D, Guerrero JR, Serrano SM. Bradykinin-potentiating peptides: beyond captopril. Toxicol. 2012;59(4):516–23.

19. Pimenta DC, Prezoto BC, Konno K, Melo RL, Furtado MF, Camargo AC, et al. Mass spectrometric analysis of the individual variability of Bothrops jararaca venom peptide fraction. Evidence for sex-based variation among the bradykinin-potentiating peptides. Rapid Commun Mass Spectrom. 2007; 21(6):1034–42.

20. Rawlings ND, Barrett AJ, Finn RD. Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2016; 44(D1):D343–50.

21. Marques-Porto R, Lebrun I, Pimenta DC. Self-proteolysis regulation in the Bothrops jararaca venom: the metallopeptidases and their intrinsic peptidic inhibitor. Comp Biochem Physiol C Toxicol Pharmacol. 2008;147(4):424–33.

22. Zelanis A, Menezes MC, Kitano ES, Liberato T, Tashima AK, Pinto AFM, et al. Proteomic identification of gender molecular markers in Bothrops jararaca venom. J Proteome. 2016;139:26–37.

23. Huang KF, Chiou SH, Ko TP, Wang AH. Determinants of the inhibition of a Taiwan habu venom metalloproteinase by its endogenous inhibitors revealed by X-ray crystallography and synthetic inhibitor analogues. Eur J Biochem. 2002;269(12):3047–56.

24. Wagstaff SC, Favreau P, Cheneval O, Laing GD, Wilkinson MC, Miller RL, et al. Molecular characterisation of endogenous snake venom metalloproteinase inhibitors. Biochem Biophys Res Commun. 2008;365(4):650–6.

25. Sciani JM, Cavalcante I, Viala VL, Chagas BB, Pimenta DC, et al. Isolation and biochemical characterization of bradykinin-potentiating peptides from Bits gabonica Rhinoceros. J Venom Anim Toxins incl Trop Dis. 2017;23:33.

26. Tanaka T, Chung GTY, Forster A, Natividad Lobato M, Rabbits TH. De novo production of diverse intracellular antibody libraries. Nucleic Acids Res. 2003;31(5):e23.

27. Hargreaves AD, Swain MT, Hegarty MJ, Logan DW, Mulley JF. Restriction and recruitment - gene duplication and the origin and evolution of snake venom toxins. Genome Biol Evol. 2014;6(8):2088–95.

28. de Camargo Gonçalves LR, Chudzinski-Tavassi AM. High molecular mass kininogen inhibits metalloproteinases of Bothrops jararaca snake venom. Biochem Biophys Res Commun. 2004;318(1):53–9.

29. Meki AR, Nassar AY, Rochat HA. Bradykinin-potentiating peptide (peptide K12) isolated from the venom of Egyptian scorpion Buthus occitanus. Peptides. 1995;16(8):1359–65.

30. Conceição K, Bruni FM, Sciani JM, Konno K, Melo RL, Antoniazzi MM, et al. Identification of bradykinin-related peptides from Phyllomedusa nordestina skin secretion using electrospray ionization tandem mass spectrometry after a single-step liquid chromatography. J Venom Anim Toxins incl Trop Dis. 2009;15(4) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1678-91992009000400004.

31. Perpetuo EA, Juliano L, Lebrun I. Biochemical and pharmacological aspects of two bradykinin-potentiating peptides obtained from trypsin hydrolysis of casein. J Protein Chem. 2003;22(7–8):601–6.

32. Ferreira LAF, Alves WE, Lucas MS, Habermehl GG. Isolation and characterization of a bradykinin potentiating peptide (BPP-S) isolated from Scaptocosa raptoria venom. Toxicon. 1996;34(5):599–603.

33. Ianzer D, Konno K, Xavier CH, Stöcklin R, Santos RA, de Camargo AC, et al. Hemorphin and hemorphin-like peptides isolated from dog pancreas and sheep brain are able to potentiate bradykinin activity in vivo. Peptides. 2006; 27(11):2067–66.